Monte Rosa Therapeutics GLUE
NASDAQ GLUE
$10.50 -0.76 (-6.75%)
At close: Oct 2, 2026 · 4:00 PM EDT

Monte Rosa Therapeutics (GLUE) Non Operating Investment Income (2022 - 2025)

Updated

Monte Rosa Therapeutics (GLUE) reported Non Operating Investment Income of $59,000 for FY2025.

Analysis

Monte Rosa Therapeutics (GLUE) Non Operating Investment Income (2022 - 2025) Analysis & Trends

  • Non Operating Investment Income has a three-year compound annual growth rate of -18.5% (FY2022 to FY2025).
  • The FY2025 figure ranks as the highest annual Non Operating Investment Income since FY2022.
  • According to Business Quant data, Non Operating Investment Income came in at $24,000 in FY2023 (-78.0%) and $109,000 in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Op. Investment Inc. (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn -
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn -
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn -
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn -
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn -
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn -
10 Monte Rosa Therapeutics 894.88 Mn 306.69 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 59,000.00
Jun 30, 2023 24,000.00
Mar 31, 2023 -131,000.00
Sep 30, 2022 -16,000.00
Mar 31, 2022 125,000.00
API Access

Monte Rosa Therapeutics Non Operating Investment Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=GLUE&period=max&api_key=YOUR_API_KEY